Drug intelligence / Profile preview

quyu shengxin

Development stage: Unknown
Lead developer: Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Administration: Oral

Overview

Quyu Shengxin is a Traditional Chinese Medicine (TCM) herbal prescription developed by the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine for the treatment of ulcerative colitis. Based on the TCM principle of 'removing stasis and generating new tissue,' the formula is designed to promote mucosal healing and regulate the intestinal immune environment. Research into its mechanism of action focuses on its ability to modulate the immune microenvironment via the regulation of serum exosome-derived microRNAs (miRNAs). It is currently being evaluated in clinical trials to optimize its implementation and provide a basis for new drug development.

Other names: Quyu Shengxin prescriptionQuyu Shengxin formula祛瘀生新方

Beyond the preview

Go deeper on quyu shengxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on quyu shengxin.

Explore the full profile